Willem Staels1,2, Yannick Verdonck1, Yves Heremans1, Gunter Leuckx1, Sofie De Groef1, Carlo Heirman3, Eelco de Koning4, Conny Gysemans5, Kris Thielemans3, Luc Baeyens1, Harry Heimberg6, Nico De Leu7,8,9. 1. Beta Cell Neogenesis (BENE), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. 2. Department of Paediatrics, Division of Paediatric Endocrinology, Ghent University, Ghent, Belgium. 3. Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium. 4. Department of Medicine, Section of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands. 5. Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium. 6. Beta Cell Neogenesis (BENE), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. Harry.Heimberg@vub.be. 7. Beta Cell Neogenesis (BENE), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. Nico.De.Leu@vub.be. 8. Department of Endocrinology, UZ Brussel, Brussels, Belgium. Nico.De.Leu@vub.be. 9. Department of Endocrinology, ASZ Aalst, Aalst, Belgium. Nico.De.Leu@vub.be.
Abstract
AIMS/HYPOTHESIS: The initial avascular period following islet transplantation seriously compromises graft function and survival. Enhancing graft revascularisation to improve engraftment has been attempted through virus-based delivery of angiogenic triggers, but risks associated with viral vectors have hampered clinical translation. In vitro transcribed mRNA transfection circumvents these risks and may be used for improving islet engraftment. METHODS: Mouse and human pancreatic islet cells were transfected with mRNA encoding the angiogenic growth factor vascular endothelial growth factor A (VEGF-A) before transplantation under the kidney capsule in mice. RESULTS: At day 7 post transplantation, revascularisation of grafts transfected with Vegf-A (also known as Vegfa) mRNA was significantly higher compared with non-transfected or Gfp mRNA-transfected controls in mouse islet grafts (2.11- and 1.87-fold, respectively) (vessel area/graft area, mean ± SEM: 0.118 ± 0.01 [n = 3] in Vegf-A mRNA transfected group (VEGF) vs 0.056 ± 0.01 [n = 3] in no RNA [p < 0.05] vs 0.063 ± 0.02 [n = 4] in Gfp mRNA transfected group (GFP) [p < 0.05]); EndoC-bH3 grafts (2.85- and 2.48-fold. respectively) (0.085 ± 0.02 [n = 4] in VEGF vs 0.030 ± 0.004 [n = 4] in no RNA [p < 0.05] vs 0.034 ± 0.01 [n = 5] in GFP [p < 0.05]); and human islet grafts (3.17- and 3.80-fold, respectively) (0.048 ± 0.013 [n = 3] in VEGF vs 0.015 ± 0.0051 [n = 4] in no RNA [p < 0.01] vs 0.013 ± 0.0046 [n = 4] in GFP [p < 0.01]). At day 30 post transplantation, human islet grafts maintained a vascularisation benefit (1.70- and 1.82-fold, respectively) (0.049 ± 0.0042 [n = 8] in VEGF vs 0.029 ± 0.0052 [n = 5] in no RNA [p < 0.05] vs 0.027 ± 0.0056 [n = 4] in GFP [p < 0.05]) and a higher beta cell volume (1.64- and 2.26-fold, respectively) (0.0292 ± 0.0032 μl [n = 7] in VEGF vs 0.0178 ± 0.0021 μl [n = 5] in no RNA [p < 0.01] vs 0.0129 ± 0.0012 μl [n = 4] in GFP [p < 0.001]). CONCLUSIONS/ INTERPRETATION: Vegf-A mRNA transfection before transplantation provides a promising and safe strategy to improve engraftment of islets and other cell-based implants.
AIMS/HYPOTHESIS: The initial avascular period following islet transplantation seriously compromises graft function and survival. Enhancing graft revascularisation to improve engraftment has been attempted through virus-based delivery of angiogenic triggers, but risks associated with viral vectors have hampered clinical translation. In vitro transcribed mRNA transfection circumvents these risks and may be used for improving islet engraftment. METHODS:Mouse and humanpancreatic islet cells were transfected with mRNA encoding the angiogenic growth factor vascular endothelial growth factor A (VEGF-A) before transplantation under the kidney capsule in mice. RESULTS: At day 7 post transplantation, revascularisation of grafts transfected with Vegf-A (also known as Vegfa) mRNA was significantly higher compared with non-transfected or Gfp mRNA-transfected controls in mouse islet grafts (2.11- and 1.87-fold, respectively) (vessel area/graft area, mean ± SEM: 0.118 ± 0.01 [n = 3] in Vegf-A mRNA transfected group (VEGF) vs 0.056 ± 0.01 [n = 3] in no RNA [p < 0.05] vs 0.063 ± 0.02 [n = 4] in Gfp mRNA transfected group (GFP) [p < 0.05]); EndoC-bH3 grafts (2.85- and 2.48-fold. respectively) (0.085 ± 0.02 [n = 4] in VEGF vs 0.030 ± 0.004 [n = 4] in no RNA [p < 0.05] vs 0.034 ± 0.01 [n = 5] in GFP [p < 0.05]); and human islet grafts (3.17- and 3.80-fold, respectively) (0.048 ± 0.013 [n = 3] in VEGF vs 0.015 ± 0.0051 [n = 4] in no RNA [p < 0.01] vs 0.013 ± 0.0046 [n = 4] in GFP [p < 0.01]). At day 30 post transplantation, human islet grafts maintained a vascularisation benefit (1.70- and 1.82-fold, respectively) (0.049 ± 0.0042 [n = 8] in VEGF vs 0.029 ± 0.0052 [n = 5] in no RNA [p < 0.05] vs 0.027 ± 0.0056 [n = 4] in GFP [p < 0.05]) and a higher beta cell volume (1.64- and 2.26-fold, respectively) (0.0292 ± 0.0032 μl [n = 7] in VEGF vs 0.0178 ± 0.0021 μl [n = 5] in no RNA [p < 0.01] vs 0.0129 ± 0.0012 μl [n = 4] in GFP [p < 0.001]). CONCLUSIONS/ INTERPRETATION:Vegf-A mRNA transfection before transplantation provides a promising and safe strategy to improve engraftment of islets and other cell-based implants.
Authors: O Eriksson; T Eich; A Sundin; A Tibell; G Tufveson; H Andersson; M Felldin; A Foss; L Kyllönen; B Langstrom; B Nilsson; O Korsgren; T Lundgren Journal: Am J Transplant Date: 2009-10-21 Impact factor: 8.086
Authors: Willem Staels; Yves Heremans; Gunter Leuckx; Naomi Van Gassen; Ciro Salinno; Sofie De Groef; Martine Cools; Eli Keshet; Yuval Dor; Harry Heimberg; Nico De Leu Journal: Diabetologia Date: 2017-03-16 Impact factor: 10.122
Authors: Andrew R Pepper; Rena Pawlick; Antonio Bruni; John Wink; Yasmin Rafiei; Doug O'Gorman; Richard Yan-Do; Boris Gala-Lopez; Tatsuya Kin; Patrick E MacDonald; A M James Shapiro Journal: Stem Cell Reports Date: 2017-06-06 Impact factor: 7.765
Authors: Abiramy Jeyagaran; Chuan-En Lu; Aline Zbinden; Andreas L Birkenfeld; Sara Y Brucker; Shannon L Layland Journal: Adv Drug Deliv Rev Date: 2022-08-21 Impact factor: 17.873
Authors: Cataldo Pignatelli; Francesco Campo; Alessia Neroni; Lorenzo Piemonti; Antonio Citro Journal: Transpl Int Date: 2022-08-25 Impact factor: 3.842